These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10556807)

  • 1. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
    Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
    Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
    Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
    Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
    Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
    Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
    Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
    Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
    J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis.
    Bracher M; Gould HJ; Sutton BJ; Dombrowicz D; Karagiannis SN
    J Immunol Methods; 2007 Jun; 323(2):160-71. PubMed ID: 17531261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
    Mezzanzanica D; Canevari S; Colnaghi MI
    Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
    Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
    Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
    Coney LR; Tomassetti A; Carayannopoulos L; Frasca V; Kamen BA; Colnaghi MI; Zurawski VR
    Cancer Res; 1991 Nov; 51(22):6125-32. PubMed ID: 1840502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth.
    Kershaw MH; Darcy PK; Trapani JA; MacGregor D; Smyth MJ
    Oncol Res; 1998; 10(3):133-42. PubMed ID: 9700724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
    Molthoff CF; Buist MR; Kenemans P; Pinedo HM; Boven E
    J Nucl Med; 1992 Nov; 33(11):2000-5. PubMed ID: 1432162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
    Zheng J; Guo Y; Ji X; Cui L; He W
    Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
    Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
    Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
    Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
    Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unidirectional potentiation of binding between two anti-FBP MAbs: evaluation of the involved mechanisms.
    Casalini P; Mezzanzanica D; Valota O; Adobati E; Tomassetti A; Colnaghi MI; Canevari S
    J Cell Biochem; 1995 May; 58(1):47-55. PubMed ID: 7642722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
    Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
    Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
    Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
    Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.